Middle East And Africa Ovarian Cancer Market Size & Outlook, 2025-2033


Middle East And Africa Ovarian Cancer Market Insights

  • According to Reed Intelligence analysis, the Middle East And Africa Ovarian Cancer Market size stood at USD 162 Million in 2024 and is forecasted to reach USD 1213.36 Million by 2033.
  • The market is projected to grow at a CAGR of 24.87% between 2026 and 2033.
  • By segment, Epithelial Tumors was the leading By Type in terms of market size in 2024.
  • Epithelial Tumors is expected to be the most lucrative By Type segment, exhibiting the fastest growth throughout the forecast period.

Other Key Findings


  • In 2024, Middle East And Africa contributed 12% to the overall global Ovarian Cancer Market size.
  • By 2033, United States is anticipated to dominate the global market based on market size.
  • United Arab Emirates is expected to witness the fastest growth within Middle East and Africa, attaining USD 560.56 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 162 Million
Market Size In 2033 USD 1213.36 Million
Largest segment Epithelial Tumors
Units Revenue in USD Million
CAGR 24.87% (2025-2033)
Segmnetation Covered
Middle East and Africa
  1. United Arab Emirates
  2. Saudi Arabia
  3. South Africa
  4. Egypt
  5. Nigeria
  6. Turkey
By Type
  1. Epithelial Tumors
  2. Germ Cell Tumors
  3. Stromal Tumors
  4. Primary Peritoneal Cancer
By Diagnosis
  1. Computed Tomography (C.T.) Scans
  2. Ultrasound
  3. Barium Enema X-Ray
  4. Magnetic Resonance Imaging (MRI) Scans
  5. Chest X-Ray
  6. Positron Emission Tomography (PET) Scan
  7. Other Diagnostic Tests
By Therapeutic Treatment
  1. Chemotherapy
  2. Radiation Therapy
  3. Targeted Therapy
  4. Hormone Therapy
  5. Other Therapeutic Treatments
  6. Surgery
By Route of Administration
  1. Oral
  2. Parenteral
  3. Others
By Drugs
  1. Mitotic Inhibitors
  2. Antirheumatics
  3. Antipsoriatics
  4. VEGF/VEGFR inhibitors
  5. PARP inhibitors
  6. Antineoplastics
  7. Others
By End-User
  1. Hospitals
  2. Diagnostic Centers
  3. Drug Stores
  4. Online Pharmacies
  5. Other End Users
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends